| Name | Title | Contact Details |
|---|
In 1988, a group of advocates, providers, and consumers created the Staten Island AIDS Task Force in response to the health crisis of HIV and AIDS in our community. For many years, the Task Force was the only non-profit community-based organization who...
Bionor Pharma is a leading biotechnology company advancing the first therapeutic vaccine towards a functional cure for HIV. The company`s focus is the research and development of peptide-based vaccines against viral diseases, primarily HIV. Bionor Pharma`s most advanced product candidate is Vacc-4x, which is also the most advanced therapeutic vaccine in the HIV space and has demonstrated a reduction of viral load in a large, randomized, controlled Phase II trial, as well as safety and tolerability. Pharma`s current clinical focus is to explore whether Vacc-4x, used with other medicines as a combination therapy, can reduce the viral load even further, and the company, through collaboration with Celgene, is investigating Vacc-4x and the HDAC inhibitor romidepsin in the REDUC study. In May 2015, Bionor Pharma announced promising results from an interim analysis of Part B of the REDUC study. In the study, Vacc-4x and romidepsin are explored as a possible treatment regimen to reduce the persistent latent viral reservoir in HIV infected patients on anti-retroviral treatment. Results are expected in the second half of 2015. Bionor Pharma is headquartered in Oslo, Norway, with offices in Copenhagen and New York.
We`re FinThrive and we believe revenue management technology will drive the future of healthcare. We pave the way for a healthcare system that ensures every transaction and patient experience is addressed holistically. FinThrive creates integrated technology that adapts with healthcare professionals – freeing them from complexity and inefficiency so they can focus on doing their best work. Our end-to-end revenue management platform provides financial teams and stakeholders with greater reliability and control to deliver better outcomes for everyone. With our vision, technology, experience and scale, we`re advancing the healthcare economy.
Cure Alzheimers Fund is a non-profit organization that funds targeted research with the highest probability of preventing, slowing, or reversing Alzheimers disease.
Dedicated Phase 1 is a Phoenix, AZ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.